logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yasuaki Arai

aichi cancer center
H指数:43
被引数:8,017

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI - A Secondary Analysis of a Multicenter Randomized Controlled Trial

不可切除性肝细胞癌行选择性肝动脉化疗栓塞术后的肝功能变化：JIVROSG-2001 PRESIDENT-ALBI——一项多中心随机对照试验的二次分析

LIVER CANCER
IF9.1
2025-12-010
OA
Kodama, Yoshihisa; Ikeda, Masafumi; Arai, Yasuaki; Inaba, Yoshitaka; Tanaka, Toshihiro; Arai, Yasunori; Sugawara, Shunsuke; Yamazaki, Hajime; Aramaki, Takeshi; Anai, Hiroshi; Morita, Shinichi; Fujinaga, Yasunari; Seki, Hiroshi; Sato, Mikio; Kamimura, Kenya; Ito, Junji; Tsurusaki, Masakatsu; Nakazawa, Tetsuro; Tokue, Hiroyuki; Abo, Daisuke; Kato, Kenichi; Hayashi, Natsuko; Sato, Osamu; Sone, Miyuki
Prospective Multicenter Observational Study of Silent Brain Infarction Following Transradial Hepatic Intervention (The MOSAIC Study)

前瞻性多中心观察性研究：经桡动脉肝干预后的静息性脑梗死（MOSAIC研究）

Journal of Vascular and Interventional Radiology
IF2.6
2025-08-060
OAAI
Yuji Koretsune; Miyuki Sone; Shintaro Kimura; Shunsuke Sugawara; Yoshihisa Kodama; Yasushi Kimura; Kaishu Tanaka; Yusuke Ono; Hiroki Higashihara; Yasuaki Arai; Masahiko Kusumoto; Noriyuki Tomiyama
Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

EMERALD-1研究中基线肿瘤负荷对结局的影响：一项关于度伐利尤单抗（D）±贝伐珠单抗（B）联合经动脉化疗栓塞（TACE）在栓塞适应症的不可切除肝细胞癌（uHCC）中的III期研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B.
Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial
FRONTIERS IN ONCOLOGY
IF3.3
2023-07-070
OAAI
Funasaka, Chikako; Hanai, Akiko; Zenda, Sadamoto; Mori, Keita; Fukui, Makoto; Hirano, Nami; Shinohara, Rie; Fuse, Nozomu; Wakabayashi, Masashi; Itagaki, Mai; Tomioka, Yutaka; Nishina, Michihiko; Arai, Yasuaki; Kogawa, Takahiro; Ozaki, Yukinori; Nishimura, Meiko; Kobayashi, Takayuki; Hara, Fumikata; Takano, Toshimi; Mukohara, Toru
A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial
LIVER CANCER
IF9.1
2023-06-0536
OAAI
Kudo, Masatoshi; Ueshima, Kazuomi; Saeki, Issei; Ishikawa, Toru; Inaba, Yoshitaka; Morimoto, Naoki; Aikata, Hiroshi; Tanabe, Nobukazu; Wada, Yoshiyuki; Kondo, Yasuteru; Tsuda, Masahiro; Nakao, Kazuhiko; Ito, Takanori; Hosaka, Tetsuya; Kawamura, Yusuke; Kuzuya, Teiji; Nojiri, Shunsuke; Ogawa, Chikara; Koga, Hironori; Hino, Keisuke; Ikeda, Masafumi; Moriguchi, Michihisa; Hisai, Takashi; Yoshimura, Kenichi; Furuse, Junji; Arai, Yasuaki
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302
LIVER CANCER
IF9.1
2022-06-1537
OAAI
Ikeda, Masafumi; Arai, Yasuaki; Inaba, Yoshitaka; Tanaka, Toshihiro; Sugawara, Shunsuke; Kodama, Yoshihisa; Aramaki, Takeshi; Anai, Hiroshi; Morita, Shinichi; Tsukahara, Yoshinori; Seki, Hiroshi; Sato, Mikio; Kamimura, Kenya; Azama, Kimei; Tsurusaki, Masakatsu; Sugihara, Eiji; Miyazaki, Masaya; Kobayashi, Tatsushi; Sone, Miyuki
Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment
LIVER CANCER
IF9.1
2022-05-0518
OAAI
Ueshima, Kazuomi; Komemushi, Atsushi; Aramaki, Takeshi; Iwamoto, Hideki; Obi, Shuntaro; Sato, Yozo; Tanaka, Toshihiro; Matsueda, Kiyoshi; Moriguchi, Michihisa; Saito, Hiroya; Sone, Miyuki; Yamagami, Takuji; Inaba, Yoshitaka; Kudo, Masatoshi; Arai, Yasuaki
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
LIVER CANCER
IF9.1
2022-02-1075
OAAI
Kudo, Masatoshi; Ueshima, Kazuomi; Ikeda, Masafumi; Torimura, Takuji; Tanabe, Nobukazu; Aikata, Hiroshi; Izumi, Namiki; Yamasaki, Takahiro; Nojiri, Shunsuke; Hino, Keisuke; Tsumura, Hidetaka; Kuzuya, Teiji; Isoda, Norio; Moriguchi, Michihisa; Aino, Hajime; Ido, Akio; Kawabe, Naoto; Nakao, Kazuhiko; Wada, Yoshiyuki; Ogasawara, Sadahisa; Yoshimura, Kenichi; Okusaka, Takuji; Furuse, Junji; Kokudo, Norihiro; Okita, Kiwamu; Johnson, Philip James; Arai, Yasuaki
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
LIVER CANCER
IF9.1
2019-10-0819
OAAI
Kudo, Masatoshi; Ueshima, Kazuomi; Chiba, Yasutaka; Ogasawara, Sadahisa; Obi, Shuntaro; Izumi, Namiki; Aikata, Hiroshi; Nagano, Hiroaki; Hatano, Etsuro; Sasaki, Yutaka; Hino, Keisuke; Kumada, Takashi; Yamamoto, Kazuhide; Imai, Yasuharu; Iwadou, Shouta; Ogawa, Chikara; Okusaka, Takuji; Kanai, Fumihiko; Arai, Yasuaki
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
LANCET GASTROENTEROLOGY & HEPATOLOGY
IF38.6
2018-06-01244
PREAI
Kudo, Masatoshi; Ueshima, Kazuomi; Yokosuka, Osamu; Ogasawara, Sadahisa; Obi, Shuntaro; Izumi, Namiki; Aikata, Hiroshi; Nagano, Hiroaki; Hatano, Etsuro; Sasaki, Yutaka; Hino, Keisuke; Kumada, Takashi; Yamamoto, Kazuhide; Imai, Yasuharu; Iwadou, Shouta; Ogawa, Chikara; Okusaka, Takuji; Kanai, Fumihiko; Akazawa, Kohei; Yoshimura, Ken-ichi; Johnson, Philip; Arai, Yasuaki
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Orantinib与安慰剂联合经导管动脉化疗栓塞治疗不可切除的肝细胞癌 (东方): 一项随机，双盲，安慰剂对照，多中心，3期研究

LANCET GASTROENTEROLOGY & HEPATOLOGY
IF38.6
2018-01-01147
PREAI
Kudo, Masatoshi; Cheng, Ann-Lii; Park, Joong-Won; Park, Jae Hyung; Liang, Po-Chin; Hidaka, Hisashi; Izumi, Namiki; Heo, Jeong; Lee, Youn Jae; Sheen, I-Shyan; Chiu, Chang-Fang; Arioka, Hitoshi; Morita, Satoshi; Arai, Yasuaki

研究方向

暂未获取到该数据
M
Miyuki Sone
H 指数:22论文数:182被引数:1,571
Y
Yoshitaka Inaba
H 指数:38论文数:291被引数:5,334
M
Masatoshi Kudo
H 指数:143论文数:2,840被引数:12.6万
U
Ukihide Tateishi
H 指数:54论文数:576被引数:1.0万
T
Takuji Okusaka
H 指数:99论文数:952被引数:5.3万
M
Masafumi Ikeda
H 指数:76论文数:1,020被引数:3.4万
T
Toshihiro Tanaka
H 指数:26论文数:205被引数:2,246
S
Shunsuke Sugawara
H 指数:14论文数:111被引数:655
T
Takeshi Aramaki
H 指数:26论文数:168被引数:2,601
K
Kazuro Sugimura
H 指数:69论文数:644被引数:1.6万